Next Article in Journal
Approaches to Manage ‘Affordability’ of High Budget Impact Medicines in Key EU Countries
Previous Article in Journal
Cost-Effectiveness of Solifenacin Compared with Oral Antimuscarinic Agents for the Treatment of Patients with Overactive Bladder in the UK
 
 
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Assessment and Diffusion of Medical Innovations in France: An Overview

by
Amélie Dubromel
1,*,
Loïc Geffroy
2,
Gilles Aulagner
3 and
Claude Dussart
2
1
Pharmacy Department, Hôpital d’Instruction des Armées Desgenettes, Lyon, France
2
Laboratoire Parcours Santé Systémique, Université Claude Bernard Lyon, Lyon, France
3
Pharmacy Department, Hospices civils de Lyon, Groupement Hospitalier Est, Bron, France
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2018, 6(1), 1458575; https://0-doi-org.brum.beds.ac.uk/10.1080/20016689.2018.1458575
Submission received: 3 December 2017 / Revised: 1 January 2018 / Accepted: 22 March 2018 / Published: 4 April 2018

Abstract

Background: In France, a significant part of health expenditure is publicly funding. This put a heavy burden on society. In an economic context requiring tight control of public spending, it seems relevant to control the diffusion of medical innovations. That is why health technology assessment is subject to an increasing interest at national level for management and approval decisions. This article provides an overview of the assessment and diffusion of medical innovation in France. Method: The data are extracted from French authorities or organisations websites and documents and from French legislative texts. In addition, regarding discussion, a search in MEDLINE database was carried out. Results: An overview of the assessment and diffusion of medical innovation in France is given by presenting the different types of medical innovations according to French health system definition (I); introducing French authorities participating to health technology assessment and describe assessment procedures of medical innovations (II); and giving details about market access process of innovative health product in France (III). Key opportunities and challenges of medical innovation assessment and diffusion in France are discussed at the end of this article. Conclusion: In France, medical innovation is considered as a crucial component for quality of care and performance of healthcare system. The aim of health technology assessment is to promote a secure and timely access to innovation for patients. Nevertheless, it appears necessary to improve regulatory mechanisms.
Keywords: innovation; health care; decision making; health technology assessment; pharmacoeconomics; market access innovation; health care; decision making; health technology assessment; pharmacoeconomics; market access

Share and Cite

MDPI and ACS Style

Dubromel, A.; Geffroy, L.; Aulagner, G.; Dussart, C. Assessment and Diffusion of Medical Innovations in France: An Overview. J. Mark. Access Health Policy 2018, 6, 1458575. https://0-doi-org.brum.beds.ac.uk/10.1080/20016689.2018.1458575

AMA Style

Dubromel A, Geffroy L, Aulagner G, Dussart C. Assessment and Diffusion of Medical Innovations in France: An Overview. Journal of Market Access & Health Policy. 2018; 6(1):1458575. https://0-doi-org.brum.beds.ac.uk/10.1080/20016689.2018.1458575

Chicago/Turabian Style

Dubromel, Amélie, Loïc Geffroy, Gilles Aulagner, and Claude Dussart. 2018. "Assessment and Diffusion of Medical Innovations in France: An Overview" Journal of Market Access & Health Policy 6, no. 1: 1458575. https://0-doi-org.brum.beds.ac.uk/10.1080/20016689.2018.1458575

Article Metrics

Back to TopTop